Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Ralfinamide

Known as: PRIRALFINAMIDE 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
Abstract Neuropathic pain is among the most common and difficult‐to‐treat types of chronic pain and is associated with sodium… Expand
  • figure 1
  • figure 2
  • figure 4
  • figure 5
  • table 1
2016
2016
The α-aminoamide family of sodium ion channel blockers have exhibited analgesic effects on neuropathic pain. Here, a series of… Expand
  • table 1
  • table 1
  • table 2
2012
2012
Ralfinamide, an original Na+ channel blocker developed for the treatment of chronic pain, inhibits monoamineoxidase-B with no… Expand
  • figure 1
  • figure 2
  • table 1
  • table 2
  • table 3
2010
2010
Ralfinamide is an α-aminoamide derivative with ion channel blocking properties, acting both peripherally and centrally through… Expand
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
2010
2010
  • D. Solomon
  • Arthritis and rheumatism
  • 2010
  • Corpus ID: 29204689
The development of the selective cyclooxygenase 2 (COX-2) inhibitors and their infamous fall from grace accelerated… Expand
2008
2008
Abstract Ralfinamide is analgesic when applied as a single dose in rodent models of stimulus‐evoked chronic pain. However, it is… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
2007
2007
Recent studies revealed that ralfinamide, a Na(+) channel blocker, suppressed tetrodotoxin-resistant Na(+) currents in dorsal… Expand
2007
2007
The endocannabinoid system is centrally involved in pain modulation. The endocannabinoid anandamide is produced ‘on demand’ by a… Expand
2005
2005
Tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ channels contribute to the abnormal spontaneous firing in dorsal root… Expand
2004
2004
  • F. Cattabeni
  • IDrugs : the investigational drugs journal
  • 2004
  • Corpus ID: 29361627